Literature DB >> 17440939

Molecular PCA3 diagnostics on prostatic fluid.

Martijn P M Q van Gils1, Erik B Cornel, Daphne Hessels, W Pim Peelen, J Alfred Witjes, Peter F A Mulders, Harry G Rittenhouse, Jack A Schalken.   

Abstract

BACKGROUND: The PCA3 test on urine can improve specificity in prostate cancer (PCa) diagnosis and could prevent unnecessary prostate biopsies. In this study, we evaluated the PCA3 test on prostatic fluid and compared this with the PCA3 test on urine in a clinical research setting.
METHODS: Prostatic fluid and urine samples from 67 men were collected following digital rectal examination (DRE). The sediments were analyzed using the quantitative APTIMA PCA3 test. The results were compared with prostate biopsy results.
RESULTS: Using a PCA3 score of 66 as a cut-off value, the test on prostatic fluid had 65% sensitivity for the detection of PCa, 82% specificity and a negative predictive value of 82%. At a cut-off value of 43, the test on urine had 61% sensitivity, 80% specificity and a negative predictive value of 80%.
CONCLUSIONS: The PCA3 test can be performed on both urine and prostatic fluid in the diagnosis of PCa with comparable results. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440939     DOI: 10.1002/pros.20564

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

1.  The influence of PSA-RNA yield on the analysis of expressed prostatic secretions (EPS) for prostate cancer diagnosis.

Authors:  Christopher Whelan; Laura Crocitto; Mark Kawachi; Kevin Chan; David Smith; Timothy Wilson; Steven Smith
Journal:  Can J Urol       Date:  2013-02       Impact factor: 1.344

Review 2.  Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers.

Authors:  Giulia Brisotto; Roberto Guerrieri; Francesca Colizzi; Agostino Steffan; Barbara Montico; Elisabetta Fratta
Journal:  Methods Mol Biol       Date:  2021

3.  Review of the literature: PCA3 for prostate cancer risk assessment and prognostication.

Authors:  Stacy Loeb; Alan W Partin
Journal:  Rev Urol       Date:  2011

4.  Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.

Authors:  Selin Merdan; Scott A Tomlins; Christine L Barnett; Todd M Morgan; James E Montie; John T Wei; Brian T Denton
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

5.  Assays for prostate cancer : changing the screening paradigm?

Authors:  Jens Hansen; Michael Rink; Markus Graefen; Shahrokh Shariat; Felix K-H Chun
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

Review 6.  Genomic signatures associated with the development, progression, and outcome of prostate cancer.

Authors:  Prateek Mendiratta; Phillip G Febbo
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 7.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.

Authors:  Richard R Drake; Krista Y White; Thomas W Fuller; Elena Igwe; Mary Ann Clements; Julius O Nyalwidhe; Robert W Given; Raymond S Lance; O John Semmes
Journal:  J Proteomics       Date:  2009-01-20       Impact factor: 4.044

8.  Newer potential biomarkers in prostate cancer.

Authors:  Jonathan L Wright; Paul H Lange
Journal:  Rev Urol       Date:  2007

Review 9.  The use of PCA3 in the diagnosis of prostate cancer.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

Review 10.  Urine biomarkers in prostate cancer.

Authors:  Guillaume Ploussard; Alexandre de la Taille
Journal:  Nat Rev Urol       Date:  2010-01-12       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.